Literature DB >> 19643405

The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.

Constanze Banz1, Ute Ungethuem2, Ralf-Juergen Kuban3, Klaus Diedrich1, Ernst Lengyel4, Daniela Hornung5.   

Abstract

OBJECTIVE: To determine whether endometriosis-associated endometrioid cancer (EAOC) is a specific entity compared with endometrioid cancer not associated with endometriosis (OC).
DESIGN: Case-control study.
SETTING: University hospital research laboratory. PATIENT(S): Seven patients with endometriosis-associated ovarian cancer EAOC and five patients each with OC, ovarian endometriosis, and benign ovaries. INTERVENTION(S): Ovarian tissue samples were collected from surgical procedures. MAIN OUTCOME MEASURE(S): We hybridized cRNA samples to the Affymetrix HG-U133A microarray chip. Representative genes were validated by real time polymerase chain reaction. RESULT(S): We identified two main groups of genes: The first group contained the genes SICA2, CCL14, and TDGF1. These genes were equally regulated in endometriosis and EAOC but not in OC and benign ovaries. The second group contained the genes StAR, SPINT1, Keratin 8, FoxM1B, FOLR1, CRABP1, and Claudin 7. They were equally regulated in EAOC and OC but not in ovarian endometriosis and benign ovaries. CONCLUSION(S): That the first group is composed of the cytokines SICA2 and CCL14 and the growth factor TDGF1 indicates that the regulation of the autoimmune system and of inflammatory cytokines may be very important in the etiology of endometriosis and EAOC. That the second group is composed of genes that play a central role in cell-cell interaction, differentiation, and cell proliferation indicates that they may be important in the development of ovarian cancer in women with endometriosis. Copyright (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19643405      PMCID: PMC4426869          DOI: 10.1016/j.fertnstert.2009.06.039

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  30 in total

1.  StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: immunohistochemical and real-time PCR studies.

Authors:  Manar Abd-Elaziz; Takuya Moriya; Jun-ichi Akahira; Takashi Suzuki; Hironobu Sasano
Journal:  Cancer Sci       Date:  2005-04       Impact factor: 6.716

2.  Secretion by human fibroblasts of monocyte chemoattractant protein-1, the product of gene JE.

Authors:  T Yoshimura; E J Leonard
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

3.  Expression of mucins and cytokeratins in ovarian cancer cell lines.

Authors:  M Stimpfl; B C Schmid; I Schiebel; D Tong; S Leodolter; A Obermair; R Zeillinger
Journal:  Cancer Lett       Date:  1999-10-18       Impact factor: 8.679

4.  Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types.

Authors:  R C Stern; R Dash; R C Bentley; M J Snyder; A F Haney; S J Robboy
Journal:  Int J Gynecol Pathol       Date:  2001-04       Impact factor: 2.762

5.  Ovarian and extraovarian endometriosis-associated cancer.

Authors:  Susan C Modesitt; Guillermo Tortolero-Luna; Jubilee B Robinson; David M Gershenson; Judith K Wolf
Journal:  Obstet Gynecol       Date:  2002-10       Impact factor: 7.661

Review 6.  Peritoneal cellular immunity and endometriosis.

Authors:  H N Ho; M Y Wu; Y S Yang
Journal:  Am J Reprod Immunol       Date:  1997-12       Impact factor: 3.886

7.  Folate-binding protein is a marker for ovarian cancer.

Authors:  I G Campbell; T A Jones; W D Foulkes; J Trowsdale
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

Review 8.  Conventional medical therapies for endometriosis.

Authors:  Valerie Montgomery Rice
Journal:  Ann N Y Acad Sci       Date:  2002-03       Impact factor: 5.691

9.  The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.

Authors:  Il-Man Kim; Timothy Ackerson; Sneha Ramakrishna; Maria Tretiakova; I-Ching Wang; Tanya V Kalin; Michael L Major; Galina A Gusarova; Helena M Yoder; Robert H Costa; Vladimir V Kalinichenko
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  The hepatocyte growth factor regulatory factors in human breast cancer.

Authors:  Christian Parr; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

View more
  17 in total

Review 1.  Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.

Authors:  S Leenen; M Hermens; P J de Vos van Steenwijk; R L M Bekkers; E M G van Esch
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

2.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

4.  Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer.

Authors:  Irina Favorskaya; Yaroslav Kainov; Galina Chemeris; Andrei Komelkov; Irina Zborovskaya; Elena Tchevkina
Journal:  Tumour Biol       Date:  2014-07-18

5.  CRABP1 provides high malignancy of transformed mesenchymal cells and contributes to the pathogenesis of mesenchymal and neuroendocrine tumors.

Authors:  Yaroslav Kainov; Irina Favorskaya; Vera Delektorskaya; Galina Chemeris; Andrei Komelkov; Anna Zhuravskaya; Lyubov Trukhanova; Elina Zueva; Bertrand Tavitian; Natalya Dyakova; Irina Zborovskaya; Elena Tchevkina
Journal:  Cell Cycle       Date:  2014-03-12       Impact factor: 4.534

6.  Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion.

Authors:  Neetu Dahiya; Kevin G Becker; William H Wood; Yongqing Zhang; Patrice J Morin
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

Review 7.  Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy.

Authors:  Diana P English; Alessandro D Santin
Journal:  Int J Mol Sci       Date:  2013-05-17       Impact factor: 5.923

8.  Endometriosis-associated ovarian cancer: a review of pathogenesis.

Authors:  Michael J Worley; William R Welch; Ross S Berkowitz; Shu-Wing Ng
Journal:  Int J Mol Sci       Date:  2013-03-06       Impact factor: 5.923

9.  Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment.

Authors:  Paulina Cybulska; Jill Tseng; Qin C Zhou; Alexia Iasonos; Deborah F Delair; Jennifer J Mueller; Kara C Long Roche; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  J Surg Oncol       Date:  2021-07-16       Impact factor: 2.885

Review 10.  The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.

Authors:  Giovanni Grandi; Angela Toss; Laura Cortesi; Laura Botticelli; Annibale Volpe; Angelo Cagnacci
Journal:  Biomed Res Int       Date:  2015-08-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.